[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"avascular-necrosis-of-the-femoral-head\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:avascular-necrosis-of-the-femoral-head":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,45,90,120,145,173],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100564627","emphasys-cup-positioning-in-tha-with-non-invasive-navigation-velys-hip-navigation-vhn-100564627",false,"NCT06631638","EMPHASYS Cup Positioning in THA With Non-Invasive Navigation (Velys Hip Navigation (VHN))","Planned vs. Actual Acetabular Cup Position in Total Hip Arthroplasty With Non-Invasive Navigation","Inclusion Criteria:\n\n1. All hip replacement component devices are to be used according to the approved indications.\n2. The subject is undergoing a standard of care primary uncemented hip replacement with the EMPHASYS cup and a CORAIL, EMPHASYS or ACTIS stem via the posterolateral, anterolateral, or direct lateral approach with the subject in the lateral decubitus position.\n3. The subject is a candidate for implantation utilizing the VELYS Hip Navigation system with CUPTIMIZE advanced\n4. Individuals who are able to speak, read, and comprehend the Informed Participant Consent Document and willing and able to provide consent for participation in the study and have authorized the transfer of his\u002Fher information to DePuy Synthes.\n5. Individuals who are willing and able to complete follow-up as specified by the study protocol.\n6. Individuals who are willing and able to complete the Subject Hip Outcomes questionnaires (i.e., FJS-12, EQ-5D-5L and Hip Evaluation) as specified by the study protocol.\n7. Individuals who are not bedridden per the discretion of the investigator.\n8. Individuals who are a minimum age of 21 years at the time of consent\n\nExclusion Criteria:\n\n1. Active local or systemic infection.\n2. Loss of musculature, neuromuscular compromise or vascular deficiency in the affected limb rendering the procedure unjustified.\n3. Poor bone quality, such as osteoporosis, where, in the surgeon's opinion, there could be considerable migration of the prosthesis or a significant chance of fracture of the femoral shaft and\u002For the lack of adequate bone to support the implant(s).\n4. Charcot's or Paget's disease.\n5. The Subject is a woman who is pregnant or lactating.\n6. Subject had a contralateral amputation.\n7. Previous partial hip replacement in affected hip.\n8. Subject has participated in a clinical investigation with an investigational product (drug or device) in the last three months.\n9. Contralateral hip was replaced less than 6 months prior to surgery date.\n10. Subject is currently involved in any personal injury litigation, medical-legal or worker's compensation claims.\n11. Subject was diagnosed and is taking prescription medications to treat a muscular disorder that limits mobility due to severe stiffness and pain such as fibromyalgia or polymyalgia.\n12. Subject has a medical condition with less than 2 years of life expectancy.\n13. Subject, in the opinion of the Investigator, is a drug or alcohol abuser or has a psychological disorder that could affect their ability to complete subject reported questionnaires or be compliant with follow-up requirements.","ALL","21 Years",{"count":19,"type":20},118,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this research is to gather clinical and radiographic (X-ray) information about EMPHASYS™ acetabular shell (also called a hip 'cup') placement in total hip replacement surgery using a non-invasive surgical navigation system called VELYS™ hip navigation system with CUPTIMIZE™ Advanced Hip-Spine Analysis software.\n\nData collected in this study will be compared with data collected from implantations using different cup positioning instrumentation and techniques to assess performance.",[26,27,28,29,30,31],"Osteoarthritis","Traumatic Arthritis","Rheumatoid Arthritis","Congential Hip Dysplasia","Avascular Necrosis of the Femoral Head","Certain Cases of Ankylosis","RECRUITING","2026-06-04",{"date":35,"type":36},"2026-06-05","ACTUAL",{"date":38,"type":36},"2025-10-24",{"date":40,"type":20},"2027-12-31",{"name":42,"class":43},"DePuy Orthopaedics","INDUSTRY",5,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":89},"100525572","autologous-bone-marrow-aspirate-treatment-for-early-stage-osteonecrosis-100525572","NCT06123481","Autologous Bone Marrow Aspirate Treatment for Early-Stage Osteonecrosis","Autologous Bone Marrow Aspirate Concentrate for the Treatment of Osteonecrosis of the Femoral Head","BATON","Inclusion Criteria\n\n* Participants who have non-traumatic osteonecrosis of the femoral head\n* Only participants who have Stage 1 or 2 osteonecrosis as assessed by the 2019 ARCO Staging System\n* No evidence of subchondral fracture\n* All osteonecrotic lesion sizes\n* All major risk factors (e.g. corticosteroids, alcohol, organ recipient) except for those listed in the exclusion criteria\n* Participants diagnosed who have femoral head osteonecrosis for which no risk factor has yet to be identified\n* Participants will include all ethnicities and races\n* Be able and willing to participate in study and return for postoperative visits\n\nExclusion Criteria\n\n* Participants who have:\n\n  * Sickle Cell disease\n  * Major trauma\n  * Post-irradiation ON\n  * Gaucher Disease\n  * Juvenile form: Legg-Calve-Perthes Disease\n  * Juvenile form: Spontaneous ON of the hip\n  * Pregnant or breastfeeding\n  * Vulnerable population; i.e., prisoners and institutionalized individuals\n* Participant is unable to undergo an MRI\n* Participants who have evidence of a subchondral fracture\n* Prior history of hip surgery, more extensive than hip arthroscopy","18 Years","90 Years",{"count":56,"type":20},192,[23],"Osteonecrosis of the femoral head (ONFH) is a debilitating musculoskeletal disease that is characterized by localized death of bone cells and associated cellular elements within the subchondral bone. If it progresses, it results in the collapse of the femoral head (ball part of the hip) giving rise to secondary arthritis. This condition is associated with marked pain and loss of function, often necessitating a joint replacement. Due to the relatively young age of onset of ONFH (often in 20s and 30s), there is great interest in utilizing joint-preserving procedures prior to the need for joint replacement. Joint-preserving procedures include core decompression (CD) with and without bone grafts or cells, vascularized and non-vascularized bone grafting, as well as osteotomies. Inconsistent results for each of these procedures have been reported and there are no Clinical Practice Guidelines or medical community consensus opinions regarding the treatment of early-stage ONFH. The hypothesis to be tested is \"Participants who have early-stage ONFH undergoing CD augmented with autogenous bone marrow aspirate concentrate will have better clinical and radiological outcomes than CD alone.\" This multi-center randomized controlled trial for early-stage ONFH is prospective and controlled for participant stage (only early-stage pre-collapse individuals) and surgical technique. Participants will be evaluated as per routine surgical follow-up, and at 6 months (telemedicine), 1- and 2- years using radiographs, MRIs, and questionnaires. This project will also explore the scientific basis for success vs. failure in individuals who have osteonecrosis, and have different demographics and bone marrow aspirate cell profiles.",[60,30],"Osteonecrosis of the Femoral Head",[62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78],"osteonecrosis","aseptic necrosis","avascular necrosis (AVN)","bone marrow aspirate","bone marrow aspirate concentrate","bone marrow cells","bone marrow","cell-based treatment","core decompression","femoral head","necrosis","bone diseases","musculoskeletal diseases","pathologic processes","hip","ONFH","AVN","2025-11-25",{"date":81,"type":36},"2025-11-26",{"date":83,"type":36},"2025-04-01",{"date":85,"type":20},"2029-07-31",{"name":87,"class":88},"Johns Hopkins University","OTHER",10,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":99,"phases":4,"briefSummary":100,"conditions":101,"keywords":104,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":119},"100600960","z1-hip-system-post-market-clinical-follow-up-study-100600960","NCT07104279","Z1 Hip System: Post-Market Clinical Follow Up Study","Multicenter, Post-Market Clinical Follow-up Study of the Z1 Femoral Hip System","Inclusion Criteria:\n\n* Patient is at least 18 years old and skeletally mature\n* Patient is physically and mentally willing and able, in the Investigator's opinion at the time of enrollment, to be compliant with the protocol, including all scheduled study evaluations\n* Patient, or the patient's legally authorized representative, is willing and able to participate in the Informed Consent process and provide their consent\n* Independent of study participation, patient is a candidate and qualifies for primary total hip or hemi-arthroplasty based on physical exam and medical history including at least one of the following:\n\n  * Advanced wear of the joint due to degenerative, post-traumatic or rheumatic diseases\n  * Acute traumatic fracture of the femoral head or neck\n  * Avascular necrosis (AVN) of the femoral head\n\nExclusion Criteria:\n\n* Revision arthroplasty\n* Acute, chronic, local, or systemic infection(s)\n* Severe muscular, neural, or vascular diseases that endanger the limb(s) involved\n* Lack of bony structures proximal or distal to the joint, so that good anchorage of the implant is unlikely or impossible\n* Total or partial absence of the muscular or ligamentous apparatus\n* Any concomitant diseases that can jeopardize the functioning and the success of the implant\n* Allergy to the implanted material, especially to metal (e.g. cobalt, chromium, nickel, etc.)\n* Local bone tumors and\u002For cysts\n* Patient has any condition that would, in the Investigator's opinion, place the patient at undue risk or interfere with the study\n* Any vulnerable subject:\n\n  * a prisoner\n  * a patient known to be pregnant\n  * mentally incompetent or unable to understand what participation in the study entails\n  * a known substance abuser",{"count":98,"type":20},150,"OBSERVATIONAL","The objectives of this study are to confirm the early to mid-term safety, performance, and clinical benefits of the Z1 Femoral Hip System in hemi-hip arthroplasty and primary total hip arthroplasty.\n\nThe primary objective of this post market clinical follow-up (PMCF) study is the assessment of safety by recording and analyzing the survival of the implant system at 2 years post-implantation. Safety will also be established by recording the incidence and frequency of revisions, complications, and adverse events. Relation of the events to implant, instrumentation, and\u002For procedure should be specified.\n\nThe secondary objective is the assessment of functional performance and clinical benefits of the Z1 Femoral Hip System demonstrated by recording patient-reported clinical outcomes measures (PROMs).",[102,103,30],"Hip Osteoarthritis","Acute Traumatic Fracture of the Femoral Head or Neck",[105,106,107,108,109],"total hip arthroplasty","total hip replacement","osteoarthritis","hemiarthroplasty","partial hip replacement","2025-11-06",{"date":112,"type":36},"2025-11-10",{"date":114,"type":36},"2025-10-13",{"date":116,"type":20},"2031-08",{"name":118,"class":43},"Zimmer Biomet",2,{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":99,"phases":4,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":144},"100266486","the-medacta-international-sms-post-marketing-surveillance-study-100266486","NCT02748408","The Medacta International SMS Post-Marketing Surveillance Study","The Medacta SMS Femoral Stem Component. A Multi-National, Multi-Centre, Clinical Surveillance Study","Inclusion Criteria:\n\n* Individuals with a severely painful and\u002For disabling hip joint with osteoarthritis, traumatic arthritis or developmental dysplasia of the hip or avascular necrosis of the femoral head.\n* In order to take part in this study, all study participants must be between the ages of 18 and 75 years of age, at the time of surgery.\n* Scheduled for a primary total hip replacement.\n\nExclusion Criteria:\n\n* Active infection\n* Pregnancy\n* Mental illness where the known condition is likely to compromise the patient's ability to consent, affect the patient's assessment of their progress or complete the 10 year cycle of follow-up appointments and reviews\n* Grossly distorted anatomy (surgeon's discretion)\n* Osteomalacia where uncemented implant fixation is contraindicated\n* Active rheumatoid arthritis.\n* Osteoporosis\n* Metabolic disorders which may impair bone formation where uncemented implant fixation is contraindicated\n* Muscular atrophy or neuromuscular disease\n* Allergy to implant material\n* Any patient who cannot or will not provide informed consent for participation in the study\n* Those whose prospects for a recovery to independent mobility would be compromised by known coexistent, medical problems","75 Years",{"count":129,"type":20},550,"This is a Post-Marketing Surveillance of SMS femoral stem prosthesis.",[132,27,133,134,30],"Arthrosis","Rheumatoid Polyarthritis","Congenital Hip Dysplasia","2025-09-23",{"date":137,"type":36},"2025-09-29",{"date":139,"type":4},"2015-07",{"date":141,"type":20},"2032-07",{"name":143,"class":43},"Medacta International SA",4,{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":16,"minAge":152,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":21,"phases":155,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":162,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":172},"100575459","desflurane-potentially-induces-postoperative-cognitive-dysfunction-in-elderly-patients-undergoing-perioperative-procedures-by-modulating-cdc42-and-clock-proteins-100575459","NCT06772558","Desflurane Potentially Induces Postoperative Cognitive Dysfunction in Elderly Patients Undergoing Perioperative Procedures by Modulating Cdc42 and Clock Proteins","The Potential Mechanism by Which Desflurane Induces Postoperative Cognitive Dysfunction in Elderly Perioperative Patients Involves the Modulation of Cdc42 and Clock Proteins, and Their Related Signaling Pathways.","Inclusion Criteria:\n\n* Age \\> 70 years\n* American Society of Anesthesiologists (ASA) physical status classification I-III\n* Scheduled to undergo elective surgery requiring general anesthesia with desflurane\n* Able and willing to provide voluntary written informed consent\n* Able to understand the study procedures and complete follow-up assessments\n\nExclusion Criteria:\n\n* Pre-existing diagnosis of dementia or any other neurodegenerative disease that could affect cognitive function\n* Preoperative Montreal Cognitive Assessment (MoCA) score \\\u003C 20\n* History of severe psychiatric disorders, including psychosis, severe depression, or bipolar disorder\n* Unstable angina, uncontrolled hypertension, or a history of myocardial infarction within the past 6 months\n* Severe chronic obstructive pulmonary disease (COPD) with significant respiratory compromise, or other significant respiratory disease\n* Severe hepatic or renal impairment, defined as Child-Pugh class C for liver disease, or glomerular filtration rate (GFR) \\\u003C 30 mL\u002Fmin\u002F1.73 m2 for kidney disease\n* History of stroke, transient ischemic attack (TIA), or other significant neurological disorders\n* History of alcohol or drug abuse\n* Patients with visual, auditory, or language impairments that would interfere with cognitive testing.\n* Known allergy or contraindication to any of the study drugs\n* Other conditions at the discretion of the investigator that could interfere with the conduct of the study or the interpretation of the results","70 Years",{"count":154,"type":20},60,[23],"This clinical trial investigates whether desflurane induces postoperative cognitive dysfunction (POCD) in elderly patients undergoing perioperative procedures by modulating Cdc42 and Clock proteins. The primary research questions are: (1) Does desflurane administration contribute to POCD in this patient population? and (2) Are alterations in Cdc42 and Clock protein levels associated with desflurane-induced POCD in elderly patients? To address these questions, elderly patients will be administered desflurane for anesthesia maintenance. Postoperative assessments will then compare blood levels of Cdc42 and Clock proteins, and examine related signaling pathways, between a control group and a POCD group.\n\nStudy participants will receive desflurane anesthesia maintained at a Bispectral Index (BIS) value of 40-60. Postoperative cognitive function will be assessed on the second day using the Montreal Cognitive Assessment (MoCA), and participants will be categorized into either a control group or a POCD group based on MoCA performance. Cognitive function and blood levels of Cdc42 and Clock proteins will be recorded. Furthermore, the study will also investigate associated signaling pathways.",[30,158,159,160,161],"Coronary Artery Disease (CAD)","Benign Prostatic Hyperplasia (BPH)","Cholecystitis","Knee Osteoarthritis","NOT_YET_RECRUITING","2025-01-12",{"date":165,"type":36},"2025-01-14",{"date":167,"type":20},"2025-02-01",{"date":169,"type":20},"2025-05-10",{"name":171,"class":88},"Xiaguang Duan",1,{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":99,"phases":4,"briefSummary":181,"conditions":182,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":197},"100456771","safety-and-performance-assessment-of-the-symbol-range-of-medical-devices-in-patients-underlying-total-hip-arthroplasty-100456771","NCT05227924","Safety and Performance Assessment of the SYMBOL Range of Medical Devices in Patients Underlying Total Hip Arthroplasty","Inclusion Criteria:\n\n* Patient age \\> 18 years at implantation.\n* Patient who will undergo, during the study's period of inclusion, a total hip arthroplasty (primary or revision) with at least one SYMBOL medical device (DEDIENNE Santé).\n* Patient informed of his\u002Fher participation and willing to participate in the study.\n* Patient able to read, write and understand French.\n\nExclusion Criteria:\n\n* Patient deprived of freedom, under guardianship\u002Fcuratorship or placed under judicial protection\n* Patient unable to follow study procedures.\n* Patient who has already been included in the study for a total hip arthroplasty (primary or revision) with at least one SYMBOL medical device.",{"count":180,"type":20},747,"The purpose of this post-market clinical follow up study is to assess the safety and effectiveness of the SYMBOL range of medical devices. The study will evaluate the outcome of Total Hip Arthroplasty using medical devices from SYMBOL range over a period of 10 years.",[183,184,185,186,30,187],"Degenerative Hip Joint Disease","Post-traumatic Osteoarthritis","Hip Arthritis","Femoral Neck Fractures","Failure of Prosthetic Joint Implant","2024-08-26",{"date":190,"type":36},"2024-08-27",{"date":192,"type":36},"2021-09-21",{"date":194,"type":20},"2034-09",{"name":196,"class":43},"Dedienne Sante S.A.S.",9]